Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Schizophrenia is characterized by negative symptoms and cognitive deficits.
• Antipsychotic medications are primary treatments, but their effects on these domains vary.

Purpose of the Study:

• To evaluate the efficacy of risperidone in treating negative symptoms and cognitive deficits in schizophrenia.
• To explore the relationship between negative symptoms and cognitive function during risperidone treatment.

Main Methods:

• A 4-week open-label study involving 25 schizophrenia patients.
• Assessment using the Positive and Negative Symptoms Scale (PANSS) and the Wisconsin Card Sorting Test (WCST).
• Cognitive function was also evaluated using two WAIS sub-tests.

Main Results:

• Significant improvements were observed in both negative and positive symptoms.
• Cognitive performance measures showed significant enhancement post-treatment.
• Wisconsin Card Sorting Test (WCST) scores correlated with negative symptom severity.

Conclusions:

• Risperidone demonstrates efficacy in alleviating negative symptoms and improving cognitive function in schizophrenia.
• A common underlying substrate for negative symptoms and cognitive deficits is suggested, responsive to risperidone.
• Cognitive deficits in schizophrenia may be partially dependent on the severity of negative symptoms.